Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Wildtype”

107 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 107 results

Testing effectiveness (Phase 2)UnknownNCT02006043
What this trial is testing

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Who this might be right for
Non-small Cell Lung Cancer
Li Zhang 54
Not applicableUnknownNCT05051592
What this trial is testing

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
National University Hospital, Singapore 40
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Looking for participantsNCT06568939
What this trial is testing

Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 150
Large-scale testing (Phase 3)Looking for participantsNCT06382129
What this trial is testing

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 680
Testing effectiveness (Phase 2)UnknownNCT02631460
What this trial is testing

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

Who this might be right for
NSCLC
Sun Yat-sen University 470
Early research (Phase 1)Study completedNCT01255657
What this trial is testing

ABT-806 in Subjects With Advanced Solid Tumor Types

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 49
Testing effectiveness (Phase 2)Study completedNCT01892527
What this trial is testing

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Who this might be right for
Colorectal Cancer MetastaticC-met Overexpression
Armando Santoro, MD 43
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT01708954
What this trial is testing

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
National Cancer Institute (NCI) 125
Testing effectiveness (Phase 2)Active Not RecruitingNCT03992456
What this trial is testing

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more
Academic and Community Cancer Research United 12
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 37
Large-scale testing (Phase 3)Ended earlyNCT01377376
What this trial is testing

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd.
Testing effectiveness (Phase 2)Ended earlyNCT01374789
What this trial is testing

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

Who this might be right for
Urinary Bladder Cancer
WiSP Wissenschaftlicher Service Pharma GmbH 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT05319574
What this trial is testing

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University 46
Testing effectiveness (Phase 2)Looking for participantsNCT06714357
What this trial is testing

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
National Cancer Institute, Naples 130
Testing effectiveness (Phase 2)UnknownNCT03703596
What this trial is testing

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Who this might be right for
Lung CancerLung Cancer Metastatic
Sichuan Cancer Hospital and Research Institute 88
Large-scale testing (Phase 3)Study completedNCT05427305
What this trial is testing

TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Efficacy
BioDlink Biopharm Co., Ltd. 549
Large-scale testing (Phase 3)Ended earlyNCT02134015
What this trial is testing

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
Daiichi Sankyo 145
Load More Results